Athena Athena

X
[{"orgOrder":0,"company":"Humanetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanetics Corporation to Present Clinical Trial Results at the Annual Meeting of the American Society for Radiation Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Humanetics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanetics Corporation Receives Funding from NIAID to Test Drug in COVID-19 Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Humanetics","sponsor":"Pharmaceutics International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanetics Corporation and Pharmaceutics International Announce Partnership in Support of BIO 300 Clinical Trials in COVID-19 Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Humanetics","sponsor":"Regenerative Medicine Minnesota","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanetics Corporation Receives Funding From Regenerative Medicine Minnesota to Study New Drug for Triple Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Humanetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanetics Corporation\u2019s BIO 300 Receives Fast Track Designation from FDA","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I"},{"orgOrder":0,"company":"Humanetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanetics Corporation Expands Long-Haul COVID-19 Trial to Additional Sites","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Humanetics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$5.1 million","upfrontCash":"Undisclosed","newsHeadline":"U.S. Department of Defense Awards $5.1 Million to Humanetics Corporation for Continued Development of Radiation Countermeasure","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I"},{"orgOrder":0,"company":"Humanetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanetics Corporation Presents at the 68th Annual International Radiation Research Society Meeting","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I"},{"orgOrder":0,"company":"Humanetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanetics Corporation Publishes Phase 1 Trial Results for BIO 300 Oral Powder","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I"},{"orgOrder":0,"company":"Humanetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanetics Corporation Announces Positive Results from Independent Data Monitoring Committee Review of Phase 2 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Humanetics","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanetics Corporation Awarded Contract from Department of Defense to Develop First FDA Approved Drug to Prevent Radiation Injury","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Humanetics","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanetics Corporation Receives Funding to Study New Drug for Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Humanetics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The funding will support a series of studies with its new drug candidate, BIO 300 (genistein), a unique, highly selective modulator of inflammation, cell cycle arrest and DNA damage repair, as a treatment for idiopathic pulmonary fibrosis.

            Lead Product(s): Genistein

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BIO 300

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Heart, Lung, and Blood Institute

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding October 24, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The agreement aims to develop Humanetics' drug, BIO 300 (genistein), a unique, highly selective modulator of inflammation, cell cycle arrest and DNA damage repair, as a medical countermeasure to prevent bodily harm caused by acute exposure to radiation.

            Lead Product(s): Genistein

            Therapeutic Area: Infections and Infectious Diseases Product Name: BIO 300

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Department of Defense

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 06, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BIO 300 (genistein) is a small molecule drug candidate which increases the killing effect of radiation on multiple tumor thus selectively protect normal tissues and to avoid protection of tumor cells. It is being developed as a treatment of inflammatory pulmonary injury.

            Lead Product(s): Genistein

            Therapeutic Area: Infections and Infectious Diseases Product Name: BIO 300

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BIO 300 (Genistein) Oral Powder is the Company’s medical countermeasure under development to prevent acute radiation syndrome (ARS). The article details results from the trial including safety, pharmacokinetics, and biomarkers in 34 healthy volunteers.

            Lead Product(s): Genistein

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: BIO 300

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 15, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BIO 300 Oral Powder (Genistein) is a new formulation that was developed to address unique operational needs of military personnel and first responders. It is a solid oral dosage formulation that is shelf-stable and can be self-administered.

            Lead Product(s): Genistein

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: BIO 300

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 25, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The new funding will be used to create, manufacture, and test a new formulation of BIO 300 (genistein) that can be self-administered using an auto injector. Auto injectors are commonly used by the military to deliver fast-acting drugs such as atropine and naloxone.

            Lead Product(s): Genistein

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: BIO 300

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: U.S. Department of Defense

            Deal Size: $5.1 million Upfront Cash: Undisclosed

            Deal Type: Funding June 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BIO 300 (genistein) is an oral drug that patients self-administer daily for 12 weeks following discharge from the hospital. The primary endpoint of the trial is 12 weeks after the start of dosing and patients will be followed for one year.

            Lead Product(s): Genistein

            Therapeutic Area: Infections and Infectious Diseases Product Name: BIO 300

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 18, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BIO 300 is under advanced development by Humanetics as a medical countermeasure to protect healthy human tissues and organs from harm caused by ionizing radiation. BIO 300 was initially discovered by researchers at the U.S.

            Lead Product(s): Genistein

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: BIO 300

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 24, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The studies will evaluate the potential of BIO 300 to prevent metastasis of triple negative breast cancer to the lungs following radiotherapy.

            Lead Product(s): Genistein

            Therapeutic Area: Oncology Product Name: BIO 300

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Regenerative Medicine Minnesota

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding June 02, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Partnership will support clinical trial studies of BIO 300 in COVID-19 patients.

            Lead Product(s): Genistein

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BIO 300

            Highest Development Status: Phase II Product Type: Small molecule

            Recipient: Pharmaceutics International

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership August 19, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY